From the beta amyloid hypothesis to AI-driven discoveries of novel biomarkers and breakthrough drugs in Alzheimer’s Disease

From the beta-amyloid hypothesis to AI-driven discoveries of novel biomarkers and breakthrough drugs in Alzheimer’s Disease

The latest, on-demand Digital Dialogue from the Lab of the Future features world-renowned presenters with a case study of the application of AI to drive ground-breaking science. Register to attend

Dr. Rudolph Tanzi is, inter alia, Vice-Chair of Neurology at Massachusetts General Hospital and Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School

John Dwyer is President and Founding Board Member of the Global Alzheimer’s Platform Foundation

Colin Hill is CEO and Co-Founder, Aitia

This recorded session is part of the Lab of the Future premium content section. It is free for registered users. Please register or submit below

Register for Premium Content

Name*
First Last
Job Title*
Company Name*
Country*
Country
Email*
- Remember me?
Name
This field is for validation purposes and should be left unchanged.

Digital Dialogues

From the beta amyloid hypothesis to AI-driven discoveries of novel biomarkers and breakthrough drugs in Alzheimer’s Disease

Register for Premium Content

Related content

Building Sustainable Laboratory Service Delivery Models

Keynote Address: Leveraging digital solutions to improve the efficiency and effectiveness of Life Science R&D

Technology of the Future

Driving Smarter Decision Making through Connected Lab